ALDX
HEALTHCAREAldeyra Therapeutics Inc
$1.74+0.02 (+1.16%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ALDX Today?
No stock-specific AI insight has been generated for ALDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.07$6.17
$1.74
Fundamentals
Market Cap$105M
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding60.3M
ALDX News
46 articles- Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics StockYahoo Finance·May 5, 2026
- Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair ValueYahoo Finance·May 1, 2026
- Discover 3 Stocks That Might Be Trading Below Estimated ValueYahoo Finance·May 1, 2026
- 3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%Yahoo Finance·Apr 29, 2026
- 3 Stocks That May Be Trading Below Their Estimated Value In April 2026Yahoo Finance·Apr 29, 2026
- April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair ValueYahoo Finance·Apr 27, 2026
- 3 Stocks That Might Be Undervalued By Up To 32.8%Yahoo Finance·Apr 27, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 26, 2026
- ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Coty Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COTYGlobeNewswire Inc.·Apr 25, 2026
- ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 21, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 21, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 19, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - LUGlobeNewswire Inc.·Apr 18, 2026
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 18, 2026
- Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their RightsGlobeNewswire Inc.·Apr 15, 2026
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & KorsinskyGlobeNewswire Inc.·Apr 13, 2026
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 12, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Trip.com Group Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 12, 2026
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 10, 2026
- 3 Stocks That May Be Undervalued By Up To 48.1% According To Intrinsic Value EstimatesYahoo Finance·Apr 10, 2026
- 3 Stocks Possibly Undervalued By Up To 47% Offering Potential ValueYahoo Finance·Apr 10, 2026
- ROSEN, A LEADING AND RANKED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 9, 2026
- 3 Stocks That May Be Trading Below Their Estimated Intrinsic ValueYahoo Finance·Apr 9, 2026
- 3 Stocks That May Be Undervalued In April 2026Yahoo Finance·Apr 9, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 8, 2026
- ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & KorsinskyGlobeNewswire Inc.·Apr 6, 2026
- ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action LawsuitGlobeNewswire Inc.·Apr 6, 2026
- ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 6, 2026
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 3, 2026
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDXGlobeNewswire Inc.·Apr 3, 2026
- Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your WatchlistYahoo Finance·Mar 25, 2026
- ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDAYahoo Finance·Mar 18, 2026
- Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejectionBiopharmadive·Mar 18, 2026
- FDA issues CRL to Aldeyra’s reproxalap drug applicationHospitalmanagement·Mar 18, 2026
- Aldeyra Therapeutics Shares Fall Pre-Bell After US FDA Response Cites Lack of Efficacy Data for Dry Eye DrugYahoo Finance·Mar 17, 2026
- Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseYahoo Finance·Mar 17, 2026
- SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold ConvictionMotley Fool·Mar 3, 2026
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million BuyMotley Fool·Mar 3, 2026
- Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?Yahoo Finance·Feb 26, 2026
Price Data
Open$0.00
Previous Close$1.72
Day High$0.00
Day Low$0.00
52 Week High$6.17
52 Week Low$1.07
52-Week Range
$1.07$6.17
$1.74
Fundamentals
Market Cap$105M
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding60.3M
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—